BIOMAT Database Logo BIOMAT Database Logo

[Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans]. 1989

A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka

In a pilot study the therapeutic effect of 2 x 500 mg etofibrate (Lipo Merz retard) on lipids and lipoproteins, fibrinolytic activity and clinical parameters was studied for four weeks in hyperlipidemic patients suffering from arteriosclerosis obliterans (Fontaine stage II/III). The study parameters were evaluated prior to and after the four weeks of treatment. Administration of etofibrate resulted in a significant decrease in serum cholesterol and triglyceride levels, the decrease in LDL-/HDL-cholesterol-ratio due mainly to an elevation of the HDL-cholesterol fraction, an increase in plasma fibrinolytic activity, an increased peripheral blood flow in the ischemic leg, and an increase in the pain-free walking distance. Thus, etofibrate applied twice daily might be recommended for the treatment of hyperlipidemic patients with signs of arteriosclerosis obliterans, Fontaine stage II/III.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D002995 Clofibric Acid An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. Clofibrinic Acid,2-(4-Chlorophenoxy)-2-methylpropionic Acid,NSC-1149,p-Chlorophenoxyisobutyrate,p-Chlorophenoxyisobutyric Acid,NSC 1149,NSC1149
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006937 Hypercholesterolemia A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesteremia,Elevated Cholesterol,High Cholesterol Levels,Cholesterol Level, High,Cholesterol Levels, High,Cholesterol, Elevated,Cholesterols, Elevated,Elevated Cholesterols,High Cholesterol Level,Hypercholesteremias,Hypercholesterolemias,Level, High Cholesterol,Levels, High Cholesterol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic
D001162 Arteriosclerosis Obliterans Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION. Obliterans, Arteriosclerosis

Related Publications

A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study.
November 2012, The International journal of artificial organs,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Study of patients with arteriosclerosis obliterans of the lower limbs].
January 1980, Polski przeglad chirurgiczny,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
January 2013, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Preoperative preparation of patients with arteriosclerosis obliterans].
March 1989, Khirurgiia,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Prognostic evaluation of patients with arteriosclerosis obliterans].
October 1994, Orvosi hetilap,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Immunological status of patients with arteriosclerosis obliterans].
January 1978, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Femoropopliteal bypass for patients with arteriosclerosis obliterans].
July 1996, Nihon Geka Gakkai zasshi,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
Muscle blood flow in patients with arteriosclerosis obliterans.
August 1958, American journal of surgery,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
Serum immunoglobulins in patients with arteriosclerosis & thromboangitis obliterans.
January 1987, The Indian journal of medical research,
A Dembińska-Kieć, and E Kostka-Trabka, and L Grodzińska, and K Bieroń, and A Kedzior, and M Basista, and A Zmuda, and E Trabka, and M Slawiński, and H Czarnecka
[Carbohydrate metblosim test in patients with arteriosclerosis obliterans].
June 1976, Orvosi hetilap,
Copied contents to your clipboard!